PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test orforglipron after two weeks at 4 °C, or accept the original certificate?

Asked 6 Nov 2025Modified 5 months agoViewed 19k times
17

Setup, so nobody has to ask: orforglipron · two weeks · 4 °C.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

How would you structure this, and what thresholds would you set in advance?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
TH
askedthreadlock719k286 Nov 2025
2Same situation here, so I will follow this one. – mateo_iglesias 2 months ago
Can you say which laboratory and which method? The answer changes with both. – coldpack_88 10 months ago
add a comment

5 Answers

Accepted answer first, then by votes
49

Accepted answer

two weeks is 14 days, and at 4 °C the ten-degree rule of thumb makes that roughly 13 refrigerated days of equivalent exposure. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 14 days will have moved one of them further than the other.

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
FC
answered · acceptedforty_two_c66k587 Feb 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
54

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

On the detail: the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
EL
answeredesben_lykke84k15816 Jan 2026
2Do you have the chromatogram for this, or just the summary figure? – Dr_Bram_Verhoeven 6 months ago
3I would gently push back on the second point — inter-laboratory spread is wider than stated. – two_point_four 7 months ago
add a comment
35

More usefully, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 4 Feb 2026 by nine_point_nine — removed a claim I could not source

shareimprove this answerflag
NN
answerednine_point_nine60k14827 Jan 2026
5Any reason to prefer ion chromatography over fluorine NMR for the counter-ion here? – Dr_Jonas_Halvorsen 10 months ago
add a comment
22

Specifically, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
TM
answeredtobias_maartens171k35819 Feb 2026
20

The part that matters: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 7 Dec 2025 by Dr_Otto_Lindqvist — updated for the 2026 guidance change

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist72k583 Dec 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.